within Pharmacolibrary.Drugs.ATC.L;

model L01EA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.36166666666666664,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.4,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 40.2
  );

  annotation(Documentation(
    info ="<html><body><p>Nilotinib is a second-generation oral tyrosine kinase inhibitor targeting BCR-ABL and is used primarily in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). It is currently approved and widely used in clinical practice for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult patients with chronic myeloid leukemia following oral administration under fasting conditions.</p><h4>References</h4><ol><li>Jonathan Trent, Mathieu Molimard,Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors.,Seminars in oncology,2011<a href='https://pubmed.ncbi.nlm.nih.gov/21419933/'>https://pubmed.ncbi.nlm.nih.gov/21419933/</a></li><li>Petra Šalamúnová, Tereza Krejčí, Pavel Ryšánek, Ivan Saloň, Jiřina Kroupová, Anna Hubatová-Vacková, Jakub Petřík, Tomáš Grus, Peter Lukáč, Petr Kozlík, Tomáš Křížek, Ondřej Dammer, Josef Beránek, Martin Šíma, Ondřej Slanař, František Štěpánek,Serum and lymph pharmacokinetics of nilotinib delivered by yeast glucan particles per os.,International journal of pharmaceutics,2023<a href='https://pubmed.ncbi.nlm.nih.gov/36693484/'>https://pubmed.ncbi.nlm.nih.gov/36693484/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EA03;
